PROTOCOL FOR A PHASE I STUDY OF INTRATHECAL MONOCLONAL ANTIBODY FRAGMENT 131I Me1-14 F(ab')2 IN PATIENTS WITH NEOPLASMS METASTATIC TO THE LEPTOMENINGES

Inclusion Criteria

DISEASE CHARACTERISTICS: Histologically confirmed neoplasm that is recurrent in the
subarachnoid space Biopsy of recurrent lesion required if original diagnosis made more
than 2 years prior to entry and CSF cytology negative Radiographic evidence of measurable
lesion in the leptomeninges (by myelography, CT, or MRI) or cytologic evidence of
malignancy in the CSF Any type of neoplasm eligible provided tumor cells (tissue or CSF
preparation) bind significantly to intact monoclonal antibody Me1-14 IgG2a or to Me1-14
F(ab')2 Patency of subarachnoid pathways demonstrated by isotopic intraventricular flow

PATIENT CHARACTERISTICS: Age: 3 and over Performance status: Karnofsky 50-100%
Hematopoietic: Absolute neutrophil count at least 1,000/mm3 Platelet count at least
100,000/mm3 Hepatic: AST less than 1.5 times upper limit of normal (ULN) Alkaline
phosphatase less than 1.5 times ULN Renal: Creatinine less than 1.2 mg/dL Other: No
allergy to iodine Not pregnant or nursing

PRIOR CONCURRENT THERAPY: Biologic therapy: Not specified Chemotherapy: At least 4 weeks
since prior antineoplastic chemotherapy unless unequivocal evidence of tumor progression
No concurrent systemic chemotherapy Endocrine therapy: Corticosteroids allowed if at
lowest possible dose and stable for at least 10 days prior to entry Radiotherapy: At least
3 months since prior radiotherapy to site of measurable disease unless unequivocal
evidence of disease progression Surgery: Not specified